Developmental toxicity of the HMG‐CoA reductase inhibitor, atorvastatin, in rats and rabbits
- 1 December 1994
- journal article
- research article
- Published by Wiley in Teratology
- Vol. 50 (6) , 387-394
- https://doi.org/10.1002/tera.1420500604
Abstract
The developmental toxicity of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, atorvastatin, was investigated in pregnant rats and rabbits given daily oral doses during organogenesis. Rats received 0, 10, 100, or 300 mg/kg on days 6–15 of gestation, and rabbits received 0, 10, 50, or 100 mg/kg on days 6–18 of gestation. Maternal and fetal parameters were evaluated on day 20 (rats) or 29 (rabbits) of gestation. Live fetuses were examined for external, visceral, and skeletal malformations and variations. At 300 mg/kg in rats, 1 treatment-related death occurred on day 12 of gestation, and maternal body weight gain and food consumption were decreased during treatment (43% and 23%, respectively). In addition, 1 animal at 300 mg/kg had total litter resorption. Increased postimplantation loss (not statistically significant) and slightly decreased fetal body weight (statistically significant only in males) were also observed at 300 mg/kg. There were no significant differences between treated and control groups in the incidence of fetal malformations or variations. No maternal or developmental toxicity was observed in rats at 10 or 100 mg/kg. In rabbits, marked maternal toxicity (7 deaths, body weight loss during and after treatment, and decreased food consumption) and abortion occurred at 100 mg/kg. At 50 mg/kg, maternal toxicity (2 deaths and 72% body weight gain suppression) and abortion also occurred. There were no treatment-related effects on live litter size or sex ratio. At 50 and 100 mg/kg, nonstatistically significant increases in postimplantation loss and decreases in gravid uterine weight were observed, and at 100 mg/kg, decreases in fetal body weight were observed relative to controls. There were no treatment-related malformations or variations in live fetuses of atorvastatin-treated rabbits. No maternal or developmental toxicity was observed in rabbits at 10 mg/kg. Thus, these studies demonstrate developmental toxicity at maternally toxic doses of atorvastatin in rats and rabbits, but no evidence of teratogenicity.Keywords
This publication has 14 references indexed in Scilit:
- Selection of the valid number of sampling units and a consideration of their combination in toxicological studies involving reproduction, teratogenesis or carcinogenesisPublished by Elsevier ,2004
- Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase InhibitorArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: Comparison with selected HMG-CoA reductase inhibitorsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1992
- Relative Lipophilicities, Solubilities, and Structure–Pharmacological Considerations of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitors Pravastatin, Lovastatin, Mevastatin, and SimvastatinJournal of Pharmaceutical Sciences, 1991
- Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductaseBiochemical and Biophysical Research Communications, 1990
- Preclinical evaluation of lovastatinThe American Journal of Cardiology, 1988
- CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal speciesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1986
- Mevalonate supplementation in pregnant rats suppresses the teratogenicity of mevinolinic acid, an inhibitor of 3‐hydroxy‐3‐methylglutaryl‐coenzyme a reductaseTeratology, 1983
- Selection of appropriate experimental units in teratologyTeratology, 1974
- A Note on the Staining of the Skeleton of Cleared Specimens with Alizarin Red SStain Technology, 1926